QIAGEN and Biotype Diagnostics GmbH today announced that they have entered into a partnership to establish Biotype Innovation GmbH ("Biotype Innovation").
The new company will develop and commercialize molecular diagnostic workflows initially for personalized healthcare applications based on QIAGEN’s proprietary ModaPlex platform, which enables customers to detect, characterize and measure up to 100 parameters simultaneously in a cost-effective and rapid manner.
The diagnostic assays developed by the Biotype Innovation are expected to add to the assay menu of the ModaPlex platform especially in the market for companion diagnostics, which are used to guide drug treatments.
“We are very pleased to join forces with Biotype. This partnership enables us to expand the menu of our unique ModaPlex platform, offer assay development services for pharma companies and thereby expand our leadership in companion diagnostics,” said Peer Schatz, CEO of QIAGEN. “As a long-standing partner with an unparalleled expertise in molecular analysis, Biotype is the natural partner for us.”
QIAGEN will contribute technology and access to its global commercialization engine to the joint venture, while Biotype Diagnostics GmbH will contribute know-how, assay development resources, and its scientific network. QIAGEN will have worldwide distribution rights for the assays, while Biotype Diagnostics will have co-distribution rights for Germany, Austria and Switzerland.
The partnership, structured as a joint venture, will have its head office based in Hellerau, Dresden, in newly refurbished facilities on the Campus of the Biotype Diagnostics GmbH. “The proximity will allow both companies to leverage synergies and share facilities where necessary”, says Dr. Wilhelm Zörgiebel, CEO of Biotype Diagnostics.